Pure Global AI
NCT06068205Not yet recruiting

COMPARATIVE ANALYSIS OF THE MORPHO-MECHANICAL PROPERTIES OF RED BLOOD CELLS EXTRACTED FROM DIABETIC PATIENTS WITH AND WITHOUT MICROVASCULAR COMPLICATIONS

Fondazione Policlinico Universitario Agostino Gemelli IRCCSClinicalTrials.govdiagnostic test
Study focus
Drug/Device/Intervention
Blood test - atomic force microscopy in the force spectroscopy mode
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Timeline & enrollment
Phase
N/A
Start date
Sep 29, 2023
End date
Sep 29, 2025
Enrollment
48 participants
Primary outcome

In 48 subjects with type 1 diabetes with and without microvascular complications, the average stiffness of red blood cells, measured using atomic force microscope and quantified using Young's modulus, will be measured.

Summary

The aim of the study is to analyse the biomechanical stiffness of red blood cells extracted
 from subjects with type I diabetes with and without microvascular complications through a
 biophysical characterization of red blood cells using microscopy, spectroscopy and scattering
 measurements. 48 subjects with type 1 diabetes, 24 with and 24 without microvascular
 complications will be enrolled. From all subjects a single blood sample will be taken to
 perform the analysis of red blood cells morpho-mechanical properties.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06068205
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06068205 through Pure Global AI's free database. This phase not specified trial is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.